Table 1.
Baseline demographics and clinical characteristics (intent to treat population; n = 12 unless otherwise noted)
| Baseline characteristic | Value |
|---|---|
| Age, years | 54.5 ± 9.48 |
| Sex, no. (%) | |
| Male | 4 (33) |
| Female | 8 (67) |
| Race, no. (%) | |
| Black | 9 (75) |
| White | 3 (25) |
| Sarcoidosis therapy, no. (%) | |
| Corticosteroid | 8 (67) |
| Methotrexate | 5 (41.6) |
| Hydroxycholoroquine | 1 (8.3) |
| None | 3 (25) |
| Prednisone (or equivalents) daily dose, mg | 20.9 ± 12.7 |
| Chest X-ray stage (n = 12) | |
| 0 | 1 |
| 1 | 0 |
| 2 | 1 |
| 3 | 6 |
| 4 | 4 |
| Spirometry, percent predicted | |
| FVC | 65.9 ± 13.4 |
| FEV1 | 58.0 ± 14.7 |
| DLco (n = 8) | 60.3 ± 25.0 |
| Severe airflow obstruction (FEV1 < 50% predicted), no. (%)a | 2 (16.7) |
| Isolated DLco reduction, no. (%) | 1 (8.3) |
| Principally restrictive disease suggested by spirometry, no. (%) | 4 (33) |
| Quality of life metrics | |
| SF-36 global score | 38.2 ± 5.1 |
| SGRQ total score | 62.5 ± 14.2 |
| Hemodynamic data | |
| Right atrial pressure, mmHg | 6.2 ± 4.0 |
| MPAP, mmHg | 34.8 ± 7.1 |
| PVR, Wood units (thermodilution) | 6.2 ± 3.6 |
| PAWP, mmHg | 10.3 ± 3.6 |
| Cardiac index, L/min/m2 (thermodilution) | 2.4 ± 0.6 |
| Oxygen and functional assessments | |
| Requires supplemental oxygen at rest, no. (%) | 5 (41.6) |
| 6-minute walk distance, m | 360.0 ± 163.3 |
| Maximum Borg score during 6MWT | 5.0 ± 2.3 |
| WHO functional class, no. (%) | |
| 2 | 7 (58.3) |
| 3 | 5 (41.6) |
| Serum pro-BNP, pg/mL (n = 8) | 77.6 ± 85.2 |
Note
Except where otherwise indicated, data are means ± SD. 6MWT: 6-minute walk test; BNP: brain natriuretic peptide; DLco: single-breath diffusing capacity for carbon monoxide; FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; MPAP: mean pulmonary artery pressure; PAWP: pulmonary artery wedge pressure; PVR: pulmonary vascular resistance; SF-36: short form 36; SGRQ: St. George’s respiratory questionnaire; WHO: World Health Organization.
a
Without proportionate decrease in FVC.